Read about our COVID-19 Response. COVID News This page includes COVID-19 related press releases and information where Cerus, INTERCEPT or pathogen reduction is mentioned. Newsroom Webinars and Podcasts Insights: Blog Recent Press Releases (COVID) December 4, 2020 Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting View Release Watch the presentation replay July 07, 2020 Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma View Release April 17, 2020 DARPA-funded microchip technology optimizes convalescent plasma therapy for COVID-19 patients View Release April 06, 2020 Cerus Corporation Provides Update on COVID-19 Related Activities View Release April 02, 2020 University Hospital Basel, Switzerland Transfuses First Two COVID-19 Patients With INTERCEPT Treated Coronavirus Convalescent Plasma View Release Recent News (COVID) December, 2020 Dr. Nina Khanna of the University Hospital of Basel, Switzerland, presented a clinical study entitled, “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study.” The study was conducted in collaboration with Cerus and Vitalant Research Institute, San Francisco; Vaccine Research and Development Laboratory, University of California, Irvine, CA; and Enable Biosciences, San Francisco, CA. The presentation described the results of a clinical study of INTERCEPT-treated COVID-19 convalescent plasma (CCP) to treat COVID-19 pneumonia patients. Watch the presentation replay March 26, 2020 Cerus Forms Group to Research Optimal Production of COVID-19 Convalescent Plasma. Cerus Corporation has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. The research group seeks to define the key characteristics that influence the efficacy of convalescent plasma, including the level and nature of anti-COVID-19 antibodies, optimal collection timing, dosing and how these influence responses to the therapy regimen. Cerus’ research group collaborators include the California Department of Public Health, the University of California, Irvine’s Vaccine Development Research Laboratory, the Vitalant Research Institute, the California National Primate Research Center, and Enable Biosciences. Read the press release May 29, 2020 Everything Old is New Again: Powerful Not-So-New Tool for the Battle Against COVID-19 Innovation HUB (WGBH-Boston) Read the article Safety and Sustainability We are focused on ensuring the safety of our team and our stakeholders as we endeavor to achieve our mission of establishing INTERCEPT as the global standard of care. In the face of the current COVID-19 pandemic, we have implemented actions to: Ensure the safety of our employees and their families Sustain continuity of our supply chain to support current and anticipated demand for our products Engage with regulatory authorities, blood centers, and national transfusion services to expand availability of the platelet supply Study the efficacy of INTERCEPT against SARS-CoV-2 Support blood centers evaluating the use of Convalescent Plasma READ OUR COVID-19 RESPONSE Global Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Policy and Tracking Opt-out Guide Legal Privacy Policy Copyright (c) 2020 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. MKT-EN 00473 v.1.0 About Cerus About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn. By continuing to use this website, you agree to the use of cookies described in our Cookies Policy. OK